Header Logo

James L. Mulshine

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine
Phone301-980-6787
ORCID ORCID Icon0000-0002-4648-9177 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Other Appointments:
    Dean, Rush Graduate College (Acting)
    Vice President, Rush University Medical Center

    Overview:
    I have worked on translational research in lung cancer including prevention and biological-based biomarker development with multiple papers and patents related to this work over the last thirty five years. My primary interest has been in the management of early lung cancer. I have served on and chair a number of national and international research advisory boards co-chaired a panel to prioritize development of all relevant biomarkers used in the SPORE program in 2003. I started and led the Upper Aerodigestive Tumor Biology Faculty in the NCI Intramural Program. I have also been involved in technology development issues for many years and served on the NIH Director’s Tech Transfer Subcommittee for nine years while in Bethesda to provide advice on the approval of CRADAs for the intramural NIH programs. Have served as Associate Provost for Research at Rush University from 2005-2015, Acting Dean of the Rush Graduate College from 2012 to the present. Over much of that time, I had the lead responsibility for developing the appropriate infrastructural foundations for biomedical research and education at Rush and worked with the faculty to sustain a productive environment for research and faculty development. Initially my capacity as Associate Provost for Research, I have worked with Dr. Josh Jacobs and the leadership of the Rush research community as we have established a CTSA-like infrastructure funded by Rush institutional support. We worked with the leadership of the ITM over the last 5 years as an affiliate member and have harmonized our research infrastructure and key functions with the corresponding ITM processes. We are now well positioned to join in ITM 2.0 as a fully functional and complementary partner to University of Chicago in achieving the new vision and goals outlined in the current submission.

    This joint CTSA submission builds on the productive legacy of the PCORI collaboration in CAPriCORN which was led initially by David Meltzer of U of C and now by the Raj Shah of Rush. Other established areas of Rush/ University of Chicago are multiple but involvement in the community research consortium, C3 and the outcomes research consortium, Chicago Learn are two excellent examples of the ongoing success of the U of C/ Rush collaborations. Now over the last several years I have worked as the Acting Dean of the Graduate College and in that capacity have been involved in the planning of the training and mentoring activities proposed in the new CTSA application. Through considerable Rush institutional investment, we bring a totally reengineered Graduate college curriculum for translational research to the new ITM 2.0 effort. I have had a series of roles with ITM 1.0 and have worked to integrate the efforts of the ITM 2.0 with CAPriCORN in relevant setting in collaboration with Dr. Richard Kennedy by cross- walking the governance documents for the PCORI funded, CAPriCORN and the latest NCATS funding opportunity announcement to minimize administrative barriers to complementary activities.

    In my leadership role in the Graduate College at Rush, I have been responsible for a complete overhaul of the laboratory-based, PhD and Masters programs including implementing a new and sustainable funding model for Rush to greatly enhance its support of translational science PhD education. Supported by the medical bioinformatics faculty at Rush, we have introduced a new rapid learning/ big data course into the Masters of Sciences in Clinical Research curriculum to help our students in the transition to a population healthcare model. We co-developed with the other Chicago AMCs, a recent professional development forum with iBIO for graduate students and post-doctoral fellows in a series that we had previously hosted with the University of Illinois in Chicago. Going forward these events will be sponsored for all Chicago academic medical centers through an inclusive ITM/iBIO collaboration. I continue to maintain a research interest in the area of early lung cancer management especially as it related to quantitative imaging.



    My ORCID is 0000-0002-4648-9177.
    My Scopus is 24285376700.
    My NIH COMMONS name is Jmulshine.

    Education:
    BA 1974 College of the Holy Cross, Worcester (Biology)
    M.D. 1977 Loyola Stritch Medical School, Chicago (Medicine)
    Residency 1980 Cleveland Clinic Foundation, Cleveland (Internal Medicine)
    Fellowship 1983 National Cancer Institute, Bethesda (Medical Oncology)

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mulshine JL, Avila RS, Rizzo AA, Estepar RSJ, McGlothlin A, Pyenson B, Hoyos J, Aldig? CR, Yankelevitz DF. Quantitative imaging workshop XIX: Utilizing quantitative thoracic imaging to optimize population health final summary. Int J Cancer. 2023 Dec 29. PMID: 38156720.
      Citations:    
    2. Lam S, Wynes MW, Connolly C, Ashizawa K, Atkar-Khattra S, Belani CP, DiNatale D, Henschke CI, Hochhegger B, Jacomelli C, Jelitto M, Jirapatnakul A, Kelly KL, Krishnan K, Kobayashi T, Logan J, Mattos J, Mayo J, McWilliams A, Mitsudomi T, Pastorino U, Polanska J, Rzyman W, Sales Dos Santos R, Scagliotti GV, Wakelee H, Yankelevitz DF, Field JK, Mulshine JL, Avila R. The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative. J Thorac Oncol. 2024 Jan; 19(1):94-105. PMID: 37595684.
      Citations:    
    3. Mulshine JL, Aldig? CR, Ambrose LF, Armato SG, Avila RS, Cham M, Estepar RSJ, Fain SB, Gazourian L, Gierada DS, Hatt C, Henschke CI, Hoyos J, Lynch DA, McGlothlin AK, Oudkerk M, Pasquinelli M, Pinsky P, Pyenson B, Rizzo AA, Ross SM, Schmitz KH, Silva M, Okwuosa T, Washko G, Wisnivesky J, Yankelevitz DF, Zulueta JJ. Emphysema Detection in the Course of Lung Cancer Screening: Optimizing a Rare Opportunity to Impact Population Health. Ann Am Thorac Soc. 2023 04; 20(4):499-503. PMID: 36490389.
      Citations:    
    4. Mulshine JL, Pyenson B. The Long, Slow Road to Lung Cancer Cure. JAMA Oncol. 2021 12 01; 7(12):1765-1767. PMID: 34673896.
      Citations:    
    5. Rizzo A, Mulshine JL. Thoracic CT screening: using routinely detectable COPD information. Clin Imaging. 2021 Oct; 78:310-312. PMID: 34140204.
      Citations:    
    6. Avila RS, Fain SB, Hatt C, Armato SG, Mulshine JL, Gierada D, Silva M, Lynch DA, Hoffman EA, Ranallo FN, Mayo JR, Yankelevitz D, Estepar RSJ, Subramaniam R, Henschke CI, Guimaraes A, Sullivan DC. QIBA guidance: Computed tomography imaging for COVID-19 quantitative imaging applications. Clin Imaging. 2021 Sep; 77:151-157. PMID: 33684789.
      Citations:    
    7. Mulshine JL, Avila RS, Conley E, Devaraj A, Ambrose LF, Flanagan T, Henschke CI, Hirsch FR, Janz R, Kakinuma R, Lam S, McWilliams A, Van Ooijen PMA, Oudkerk M, Pastorino U, Reeves A, Rogalla P, Schmidt H, Sullivan DC, Wind HHJ, Wu N, Wynes M, Xueqian X, Yankelevitz DF, Field JK. The International Association for the Study of Lung Cancer Early Lung Imaging Confederation. JCO Clin Cancer Inform. 2020 02; 4:89-99. PMID: 32027538.
      Citations:    
    8. Mulshine JL, Ujhazy P, Antman M, Burgess CM, Kuzmin I, Bunn PA, Johnson BE, Roth JA, Pass HI, Ross SM, Aldige CR, Wistuba II, Minna JD. From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2019 Dec 05. PMID: 31803961.
      Citations:    
    9. Field JK, deKoning H, Oudkerk M, Anwar S, Mulshine J, Pastorino U, Eberhardt W, Prosch H. Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion. ESMO Open. 2019; 4(5):e000577. PMID: 31673428.
      Citations:    
    10. Mulshine JL. One Screening for Ischemic Heart Disease, Lung Cancer, and Chronic Obstructive Pulmonary Disease: A Systems Biology Bridge for Tobacco and Radiation Exposure. Am J Public Health. 2018 10; 108(10):1294-1295. PMID: 30207781.
      Citations:    
    11. Mulshine JL. Status of lung cancer screening. J Thorac Dis. 2017 Nov; 9(11):4311-4314. PMID: 29266114.
      Citations:    
    12. Rydzak CE, Armato SG, Avila RS, Mulshine JL, Yankelevitz DF, Gierada DS. Quality assurance and quantitative imaging biomarkers in low-dose CT lung cancer screening. Br J Radiol. 2018 Oct; 91(1090):20170401. PMID: 28830225.
      Citations:    
    13. Sevick-Muraca EM, Frank RA, Giger ML, Mulshine JL. Moonshot Acceleration Factor: Medical Imaging. Cancer Res. 2017 11 01; 77(21):5717-5720. PMID: 28993413.
      Citations:    
    14. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
      Citations:    
    15. Mulshine JL, Ambrose LF. Implementing computed tomography-based lung cancer screening in the community. J Thorac Dis. 2016 Oct; 8(10):E1304-E1306. PMID: 27867613.
      Citations:    
    16. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017 01 21; 389(10066):299-311. PMID: 27574741.
      Citations:    
    17. Ma X, Siegelman J, Paik DS, Mulshine JL, St Pierre S, Buckler AJ. Volumes Learned: It Takes More Than Size to "Size Up" Pulmonary Lesions. Acad Radiol. 2016 09; 23(9):1190-8. PMID: 27287713.
      Citations:    
    18. Rzyman W, Mulshine JL. Lung cancer screening moving forward. Ann Transl Med. 2016 Apr; 4(8):149. PMID: 27195267.
      Citations:    
    19. Mulshine JL, Avila R, Yankelevitz D, Baer TM, Est?par RSJ, Ambrose LF, Aldig? CR. Lung Cancer Workshop XI: Tobacco-Induced Disease: Advances in Policy, Early Detection and Management. J Thorac Oncol. 2015 May; 10(5):762-767. PMID: 25898957.
      Citations:    
    20. Mulshine JL, Gierada DS, Armato SG, Avila RS, Yankelevitz DF, Kazerooni EA, McNitt-Gray MF, Buckler AJ, Sullivan DC. Role of the Quantitative Imaging Biomarker Alliance in optimizing CT for the evaluation of lung cancer screen-detected nodules. J Am Coll Radiol. 2015 Apr; 12(4):390-5. PMID: 25842017.
      Citations:    
    21. Mulshine JL, Yankelevitz DF. Shared decision making and screening: an ongoing dialogue informed by data. Oncology (Williston Park). 2015 Mar; 29(3):149. PMID: 25772452.
      Citations:    
    22. Mulshine JL. Lung cancer screening with low-dose CT: more questions than answers--author's reply. Lancet Oncol. 2015 Jan; 16(1):e4. PMID: 25638555.
      Citations:    
    23. Rinewalt D, Williams BW, Reeves AP, Shah P, Hong E, Mulshine JL. Evaluation of an interactive science publishing tool: toward enabling three-dimensional analysis of medical images. Acad Radiol. 2015 Mar; 22(3):380-6. PMID: 25499105.
      Citations:    
    24. Mulshine JL, Henschke CI. Lung cancer screening: achieving more by intervening less. Lancet Oncol. 2014 Nov; 15(12):1284-5. PMID: 25282286.
      Citations:    
    25. Mulshine JL, D'Amico TA. Issues with implementing a high-quality lung cancer screening program. CA Cancer J Clin. 2014 Sep-Oct; 64(5):352-63. PMID: 24976072.
      Citations:    
    26. Gulati S, Mulshine JL. Lung cancer screening guidelines: common ground and differences. Transl Lung Cancer Res. 2014 Jun; 3(3):131-8. PMID: 25806292.
      Citations:    
    27. Cummings KM, Dresler CM, Field JK, Fox J, Gritz ER, Hanna NH, Ikeda N, Jassem J, Mulshine JL, Peters MJ, Yamaguchi NH, Warren G, Zhou C. E-cigarettes and cancer patients. J Thorac Oncol. 2014 Apr; 9(4):438-41. PMID: 24736063.
      Citations:    
    28. Mulshine JL, Healton C. Tobacco control since the 1964 Surgeon General's Report: reflecting back and looking forward. Oncology (Williston Park). 2014 Mar; 28(3):180, 182-3, 210. PMID: 24855724.
      Citations:    
    29. Field JK, Aberle DR, Altorki N, Baldwin DR, Dresler C, Duffy SW, Goldstraw P, Hirsch FR, Pedersen JH, de Koning HJ, Mulshine JL, Sullivan DC, Tsao MS, Travis WD. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. J Thorac Oncol. 2014 Feb; 9(2):141-3. PMID: 24419409.
      Citations:    
    30. Fang C, Man YG, Cuttitta F, Stetler-Stevenson W, Salomon D, Mazar A, Kulesza P, Rosen S, Avital I, Stojadinovic A, Jewett A, Jiang B, Mulshine J. Novel Phenotypic Fluorescent Three-Dimensional Co-Culture Platforms for Recapitulating Tumor in vivo Progression and for Personalized Therapy. J Cancer. 2013; 4(9):755-63. PMID: 24312145.
      Citations:    
    31. Mulshine JL, Avila R, Yankelevitz D, Baer TM, Estepar RS, Fenton L, Aldige CR. Application of high-resolution CT imaging data to lung cancer drug development: measuring progress: workshop IX. J Thorac Oncol. 2013 Nov; 8(11):1352-5. PMID: 24128711.
      Citations:    
    32. Mulshine JL. Advancing patient-centric genomic medicine. Oncology (Williston Park). 2013 Sep; 27(9):827. PMID: 24282976.
      Citations:    
    33. Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, Dresler CA. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract. 2013 Sep; 9(5):258-62. PMID: 23943904.
      Citations:    
    34. Hanna N, Mulshine J, Wollins DS, Tyne C, Dresler C. Tobacco cessation and control a decade later: American society of clinical oncology policy statement update. J Clin Oncol. 2013 Sep 01; 31(25):3147-57. PMID: 23897958.
      Citations:    
    35. Mulshine JL. Lessons from considering the cancer landscape. Oncology (Williston Park). 2013 May; 27(5):408, 410. PMID: 25184263.
      Citations:    
    36. Mulshine JL, Ondrey FG. Not significant but important. Cancer Prev Res (Phila). 2013 May; 6(5):371-4. PMID: 23639860.
      Citations:    
    37. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):33-8. PMID: 22710039.
      Citations:    
    38. Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Sugarbaker DJ, Swanson SJ, Travis WD, Jaklitsch MT. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):25-32. PMID: 22710038.
      Citations:    
    39. Pyenson BS, Sander MS, Jiang Y, Kahn H, Mulshine JL. An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. Health Aff (Millwood). 2012 Apr; 31(4):770-9. PMID: 22492894.
      Citations:    
    40. Field JK, Smith RA, Aberle DR, Oudkerk M, Baldwin DR, Yankelevitz D, Pedersen JH, Swanson SJ, Travis WD, Wisbuba II, Noguchi M, Mulshine JL. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012 Jan; 7(1):10-9. PMID: 22173661.
      Citations:    
    41. Mulshine JL, van Klaveren RJ. Lung cancer screening: what is the benefit and what do we do about it? Lung Cancer. 2011 Mar; 71(3):247-8. PMID: 21277040.
      Citations:    
    42. Tauler J, Zudaire E, Liu H, Shih J, Mulshine JL. hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res. 2010 Sep 15; 70(18):7137-47. PMID: 20807810.
      Citations:    
    43. Mulshine JL, Baer TM, Avila RS. Introduction: Imaging in diagnosis and treatment of lung cancer. Opt Express. 2010 Jul 05; 18(14):15242-3. PMID: 20640010.
      Citations:    
    44. Avila RS, Zulueta JJ, Shara NM, Jansen K, Veronesi G, Wang H, Mulshine JL. A quantitative method for estimating individual lung cancer risk. Acad Radiol. 2010 Jul; 17(7):830-40. PMID: 20540908.
      Citations:    
    45. Chow G, Tauler J, Mulshine JL. Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol. 2010; 2010:485468. PMID: 20671927.
      Citations:    
    46. Goldberg SW, Mulshine JL, Hagstrom D, Pyenson BS. An actuarial approach to comparing early stage and late stage lung cancer mortality and survival. Popul Health Manag. 2010 Feb; 13(1):33-46. PMID: 20158322.
      Citations:    
    47. Buckler AJ, Mulshine JL, Gottlieb R, Zhao B, Mozley PD, Schwartz L. The use of volumetric CT as an imaging biomarker in lung cancer. Acad Radiol. 2010 Jan; 17(1):100-6. PMID: 19969253.
      Citations:    
    48. Mulshine JL, Jablons DM. Volume CT for diagnosis of nodules found in lung-cancer screening. N Engl J Med. 2009 Dec 03; 361(23):2281-2. PMID: 19955529.
      Citations:    
    49. Tauler J, Mulshine JL. Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol. 2009 Aug; 9(4):384-8. PMID: 19570713.
      Citations:    
    50. Mulshine JL, Avila R, Yankelevitz D, Baer TM. Use of high-resolution CT imaging data in lung cancer drug development: measuring progress. Oncology (Williston Park). 2009 Apr 30; 23(5):434-8. PMID: 19476277.
      Citations:    
    51. Tauler J, Mulshine JL. Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer. PPAR Res. 2008; 2008:750238. PMID: 19277204.
      Citations:    
    52. Mulshine JL. Commentary: lung cancer screening--progress or peril. Oncologist. 2008 Apr; 13(4):435-8. PMID: 18448558.
      Citations:    
    53. Veronesi G, Bellomi M, Mulshine JL, Pelosi G, Scanagatta P, Paganelli G, Maisonneuve P, Preda L, Leo F, Bertolotti R, Solli P, Spaggiari L. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer. 2008 Sep; 61(3):340-9. PMID: 18308420.
      Citations:    
    54. Mayburd AL, Golovchikova I, Mulshine JL. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. Bioinformatics. 2008 Feb 01; 24(3):389-95. PMID: 17925305.
      Citations:    
    55. Baer TM, Mulshine JL, Jacobs JJ. Biomedical imaging archive network. Skeletal Radiol. 2007 Sep; 36(9):799-801. PMID: 17410352.
      Citations:    
    56. Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6. PMID: 17409997.
      Citations:    
    57. Mulshine JL. Early lung cancer detection: approaching the 'tipping point'? Oncology (Williston Park). 2006 Nov; 20(12):1632. PMID: 17153912.
      Citations:    
    58. Mulshine JL, Avila RS, Hirsch FR, Yankelevitz D. Developing CT image-processing tools to accelerate progress in lung cancer drug development. Oncology (Williston Park). 2006 Nov; 20(12):1606, 1608-10, 1614 passim. PMID: 17153911.
      Citations:    
    59. Field JK, Smith RA, Duffy SW, Berg CD, van Klaveren R, Henschke CI, Carbone D, Postmus PE, Paci E, Hirsch FR, Mulshine JL. The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. J Thorac Oncol. 2006 Jun; 1(5):497-8. PMID: 17409906.
      Citations:    
    60. Ganti AK, Mulshine JL. Lung cancer screening. Oncologist. 2006 May; 11(5):481-7. PMID: 16720848.
      Citations:    
    61. Mayburd AL, Martl?nez A, Sackett D, Liu H, Shih J, Tauler J, Avis I, Mulshine JL. Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. Clin Cancer Res. 2006 Mar 15; 12(6):1820-7. PMID: 16551867.
      Citations:    
    62. Mulshine JL. Current issues in lung cancer screening. Oncology (Williston Park). 2005 Nov; 19(13):1724-30; discussion 1730-1. PMID: 16425524.
      Citations:    
    63. Mulshine JL. Chemoprevention of head and neck cancer. Clin Adv Hematol Oncol. 2005 Oct; 3(10):763-5. PMID: 16258484.
      Citations:    
    64. Mulshine JL. Clinical issues in the management of early lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4993s-4998s. PMID: 16000602.
      Citations:    
    65. Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. PMID: 16000599.
      Citations:    
    66. Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med. 2005 Jun 30; 352(26):2714-20. PMID: 15987920.
      Citations:    
    67. Avis I, Mart?nez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, Ondrey F, Mulshine JL. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res. 2005 May 15; 65(10):4181-90. PMID: 15899809.
      Citations:    
    68. Mulshine JL. New developments in lung cancer screening. J Clin Oncol. 2005 May 10; 23(14):3198-202. PMID: 15886306.
      Citations:    
    69. Man YG, Zhang Y, Shen T, Zeng X, Tauler J, Mulshine JL, Strauss BL. cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: implications for breast tumor invasion. Breast Cancer Res Treat. 2005 Jan; 89(2):199-208. PMID: 15692763.
      Citations:    
    70. Man YG, Shen T, Weisz J, Berg PE, Schwartz AM, Mulshine JL, Sang QX, Nieburgs HE. A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. Cancer Detect Prev. 2005; 29(4):323-31. PMID: 16122886.
      Citations:    
    71. Ganti AK, Mulshine JL. Lung cancer screening: panacea or pipe dream? Ann Oncol. 2005; 16 Suppl 2:ii215-9. PMID: 15958460.
      Citations:    
    72. Mulshine JL, Neckers L. Epithelial-directed drug delivery: influence of formulation and delivery devices. Lung Cancer. 2004 Dec; 46(3):387-92. PMID: 15541828.
      Citations:    
    73. Mulshine JL, Weinstein JN. Is the gene expression pattern of lung cancer detected by screening with spiral computed tomography different from that of symptom-detected lung cancer? Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):5973-4. PMID: 15447979.
      Citations:    
    74. Hattery D, Hattery B, Chernomordik V, Smith P, Loew M, Mulshine J, Gandjbakhche A. Differential oblique angle spectroscopy of the oral epithelium. J Biomed Opt. 2004 Sep-Oct; 9(5):951-60. PMID: 15447016.
      Citations:    
    75. Warner EE, Mulshine JL. Lung cancer screening with spiral CT: toward a working strategy. Oncology (Williston Park). 2004 May; 18(5):564-75, discussion 578, 583-4, 587. PMID: 15209187.
      Citations:    
    76. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004 Mar 01; 10(5):1565-73. PMID: 15014005.
      Citations:    
    77. Warner EE, Mulshine JL. Surgical considerations with lung cancer screening. J Surg Oncol. 2003 Sep; 84(1):1-6. PMID: 12949983.
      Citations:    
    78. Mulshine JL, Hirsch FR. Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer. 2003 Aug; 41 Suppl 1:S163-74. PMID: 12867075.
      Citations:    
    79. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer. 2003 Jul; 5(1):46-62. PMID: 14596704.
      Citations:    
    80. Garayoa M, Man YG, Mart?nez A, Cuttitta F, Mulshine JL. Downregulation of hnRNP A2/B1 expression in tumor cells under prolonged hypoxia. Am J Respir Cell Mol Biol. 2003 Jan; 28(1):80-5. PMID: 12495935.
      Citations:    
    81. Martínez A, Lehman TA, Modali R, Mulshine JL. Screening of mutations in the ras family of oncogenes by polymerase chain reaction-based ligase chain reaction. Methods Mol Med. 2003; 74:187-200. PMID: 12415694.
      Citations:    
    82. Mulshine JL. Screening for lung cancer: in pursuit of pre-metastatic disease. Nat Rev Cancer. 2003 Jan; 3(1):65-73. PMID: 12509768.
      Citations:    
    83. Mulshine JL, Smith RA, Field JK, Hirsch FR. Tobacco money: up in smoke? Lancet. 2002 Dec 14; 360(9349):1979-80; author reply 1981. PMID: 12493299.
      Citations:    
    84. Mulshine JL, Smith RA. Lung cancer. 2: screening and early diagnosis of lung cancer. Thorax. 2002 Dec; 57(12):1071-8. PMID: 12454304.
      Citations:    
    85. van Klaveren RJ, de Koning HJ, Mulshine J, Hirsch FR. Lung cancer screening by spiral CT. What is the optimal target population for screening trials? Lung Cancer. 2002 Dec; 38(3):243-52. PMID: 12445745.
      Citations:    
    86. Hirsch FR, Bunn PA, Dmitrovsky E, Field JK, Franklin WA, Greenberg RE, Hansen HH, Henschke CI, Rigas JR, Smith RA, Toennesen P, Mulshine JL. IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. Lung Cancer. 2002 Sep; 37(3):325-44. PMID: 12234703.
      Citations:    
    87. Bastarrika G, Pueyo JC, Mulshine JL. Radiologic screening for lung cancer. Expert Rev Anticancer Ther. 2002 Aug; 2(4):385-92. PMID: 12647981.
      Citations:    
    88. Field JK, Brambilla C, Caporaso N, Flahault A, Henschke C, Herman J, Hirsch F, Lachmann P, Lam S, Maier S, Montuenga LM, Mulshine J, Murphy M, Pullen J, Spitz M, Tockman M, Tyndale R, Wistuba I, Youngson J. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol. 2002 Aug; 21(2):369-73. PMID: 12118333.
      Citations:    
    89. Mulshine JL, Cuttitta F, Tockman MS, De Luca LM. Lung cancer evolution to preinvasive management. Clin Chest Med. 2002 Mar; 23(1):37-48. PMID: 11901918.
      Citations:    
    90. Mulshine JL, Hong S, Mart?nez A, Tauler J, Avis I, Tockman MS, De Luca LM, Placke ME, Cuttitta F. Moving to the routine management of pre symptomatic lung cancer. Lung Cancer. 2001 Dec; 34 Suppl 2:S1-5. PMID: 11720735.
      Citations:    
    91. Zhou J, Nong L, Wloch M, Cantor A, Mulshine JL, Tockman MS. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):341-50. PMID: 11714531.
      Citations:    
    92. Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J. 2001 Sep; 15(11):2007-9. PMID: 11511519.
      Citations:    
    93. Zhou J, Allred DC, Avis I, Martínez A, Vos MD, Smith L, Treston AM, Mulshine JL. Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res Treat. 2001 Apr; 66(3):217-24. PMID: 11510693.
      Citations:    
    94. Mulshine JL, Day RW. Screening for lung cancer. N Engl J Med. 2001 Mar 22; 344(12):935-6. PMID: 11263428.
      Citations:    
    95. Mulshine JL, De Luca LM, Dedrick RL, Tockman MS, Webster R, Placke ME. Considerations in developing successful, population-based molecular screening and prevention of lung cancer. Cancer. 2000 Dec 01; 89(11 Suppl):2465-7. PMID: 11147628.
      Citations:    
    96. Tockman MS, Mulshine JL. The early detection of occult lung cancer. Chest Surg Clin N Am. 2000 Nov; 10(4):737-49. PMID: 11091923.
      Citations:    
    97. Man YG, Martinez A, Avis IM, Hong SH, Cuttitta F, Venzon DJ, Mulshine JL. Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am J Respir Cell Mol Biol. 2000 Nov; 23(5):636-45. PMID: 11062142.
      Citations:    
    98. Wang DL, Marko M, Dahl AR, Engelke KS, Placke ME, Imondi AR, Mulshine JL, De Luca LM. Topical delivery of 13-cis-retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors. Clin Cancer Res. 2000 Sep; 6(9):3636-45. PMID: 10999756.
      Citations:    
    99. Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, Cavanaugh PF, Van Waes C, Mulshine JL. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J. 2000 Aug; 14(11):1499-507. PMID: 10928984.
      Citations:    
    100. Dahl AR, Grossi IM, Houchens DP, Scovell LJ, Placke ME, Imondi AR, Stoner GD, De Luca LM, Wang D, Mulshine JL. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res. 2000 Aug; 6(8):3015-24. PMID: 10955779.
      Citations:    
    101. Mulshine JL, Henschke CI. Prospects for lung-cancer screening. Lancet. 2000 Feb 19; 355(9204):592-3. PMID: 10696976.
      Citations:    
    102. Montuenga LM, Mulshine JL. New molecular strategies for early lung cancer detection. Cancer Invest. 2000; 18(6):555-63. PMID: 10923104.
      Citations:    
    103. Mulshine JL. Reducing lung cancer risk: early detection. Chest. 1999 Dec; 116(6 Suppl):493S-496S. PMID: 10619517.
      Citations:    
    104. Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, Larson SM, Cuttitta F, Johnson BE, Mulshine JL. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3385-93. PMID: 10589749.
      Citations:    
    105. Hong SH, Avis I, Vos MD, Mart?nez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999 May 01; 59(9):2223-8. PMID: 10232612.
      Citations:    
    106. Mulshine JL. Reflections on early cancer control efforts. J Surg Oncol. 1999 Apr; 70(4):207-8. PMID: 10219014.
      Citations:    
    107. Iwai N, Mart?nez A, Miller MJ, Vos M, Mulshine JL, Treston AM. Autocrine growth loops dependent on peptidyl alpha-amidating enzyme as targets for novel tumor cell growth inhibitors. Lung Cancer. 1999 Mar; 23(3):209-22. PMID: 10413197.
      Citations:    
    108. Anderson KM, Seed T, Vos M, Mulshine J, Meng J, Alrefai W, Ou D, Harris JE. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate. 1998 Nov 01; 37(3):161-73. PMID: 9792133.
      Citations:    
    109. Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, Frincke JM, Lollo CP, Larson SM, Carrasquillo JA. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 1998 Nov; 4(11):2691-700. PMID: 9829731.
      Citations:    
    110. Montuenga LM, Zhou J, Avis I, Vos M, Martinez A, Cuttitta F, Treston AM, Sunday M, Mulshine JL. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. Am J Respir Cell Mol Biol. 1998 Oct; 19(4):554-62. PMID: 9761751.
      Citations:    
    111. Moody TW, Leyton J, Martinez A, Hong S, Malkinson A, Mulshine JL. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res. 1998 Jul-Aug; 24(4):617-28. PMID: 9659587.
      Citations:    
    112. Zhou J, Mulshine JL, Ro JY, Avis I, Yu R, Lee JJ, Morice R, Lippman SM, Lee JS. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. Clin Cancer Res. 1998 Jul; 4(7):1631-40. PMID: 9676837.
      Citations:    
    113. Hida T, Leyton J, Makheja AN, Ben-Av P, Hla T, Martinez A, Mulshine J, Malkani S, Chung P, Moody TW. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 1998 Mar-Apr; 18(2A):775-82. PMID: 9615719.
      Citations:    
    114. Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, Ruckdeschel JC, Taylor PR, Zhukov T, Zhou WH, Qiao YL, Yao SX. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2237-46. PMID: 9815620.
      Citations:    
    115. Tockman MS, Mulshine JL. Sputum screening by quantitative microscopy: a new dawn for detection of lung cancer? Mayo Clin Proc. 1997 Aug; 72(8):788-90. PMID: 9276609.
      Citations:    
    116. Kelley MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL, Johnson BE. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 1997 Jul; 112(1):256-61. PMID: 9228385.
      Citations:    
    117. Mulshine JL, Scott F, Zhou J, Avis I, Vos M, Treston AM. Recent molecular advances in the approach to early lung cancer detection and intervention. Environ Health Perspect. 1997 Jun; 105 Suppl 4:935-9. PMID: 9255584.
      Citations:    
    118. Hirsch FR, Brambilla E, Gray N, Gritz E, Kelloff GJ, Linnoila RI, Pastorino U, Mulshine JL. Prevention and early detection of lung cancer-clinical aspects. Lung Cancer. 1997 May; 17(1):163-74. PMID: 9194035.
      Citations:    
    119. Mulshine JL, Zhou J, Treston AM, Szabo E, Tockman MS, Cuttitta F. New approaches to the integrated management of early lung cancer. Hematol Oncol Clin North Am. 1997 Apr; 11(2):235-52. PMID: 9137968.
      Citations:    
    120. Scott FM, Modali R, Lehman TA, Seddon M, Kelly K, Dempsey EC, Wilson V, Tockman MS, Mulshine JL. High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin Cancer Res. 1997 Mar; 3(3):479-82. PMID: 9815708.
      Citations:    
    121. Lehman TA, Scott F, Seddon M, Kelly K, Dempsey EC, Wilson VL, Mulshine JL, Modali R. Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction. Anal Biochem. 1996 Aug 01; 239(2):153-9. PMID: 8811898.
      Citations:    
    122. Weinberg I, Majewski S, Weisenberger A, Markowitz A, Aloj L, Majewski L, Danforth D, Mulshine J, Cowan K, Zujewski J, Chow C, Jones E, Chang V, Berg W, Frank J. Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. Eur J Nucl Med. 1996 Jul; 23(7):804-6. PMID: 8662120.
      Citations:    
    123. Scott FM, Treston AM, Shaw GL, Avis I, Sorenson J, Kelly K, Dempsey EC, Cantor AB, Tockman M, Mulshine JL. Peptide amidating activity in human bronchoalveolar lavage fluid. Lung Cancer. 1996 Jun; 14(2-3):239-51. PMID: 8794407.
      Citations:    
    124. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem. 1996 May 10; 271(19):11477-83. PMID: 8626706.
      Citations:    
    125. Zhou J, Mulshine JL, Unsworth EJ, Scott FM, Avis IM, Vos MD, Treston AM. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J Biol Chem. 1996 May 03; 271(18):10760-6. PMID: 8631886.
      Citations:    
    126. Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996 Mar; 14(3):806-13. PMID: 8622028.
      Citations:    
    127. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Mart?nez A, Mulshine JL. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996 Feb 01; 97(3):806-13. PMID: 8609238.
      Citations:    
    128. Zhou J, Jensen SM, Steinberg SM, Mulshine JL, Linnoila RI. Expression of early lung cancer detection marker p31 in neoplastic and non-neoplastic respiratory epithelium. Lung Cancer. 1996 Feb; 14(1):85-97. PMID: 8696723.
      Citations:    
    129. Shaw GL, Gazdar AF, Phelps R, Steinberg SM, Linnoila RI, Johnson BE, Oie HK, Russell EK, Ghosh BC, Pass HI, Minna JD, Mulshine JL, Ihde DC. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85. PMID: 8806100.
      Citations:    
    130. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA, Carney D, Minna JD, Mulshine JL. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996; 24:32-91. PMID: 8806092.
      Citations:    
    131. Weiner RE, Avis I, Neumann RD, Mulshine JL. Transferrin dependence of Ga (NO3)3 inhibition of growth in human-derived small cell lung cancer cells. J Cell Biochem Suppl. 1996; 24:276-87. PMID: 8806110.
      Citations:    
    132. Quinn KA, Unsworth EJ, Miller MJ, Mulshine JL, Cuttitta F. Biochemical characterization of mouse liver IBE1-amide immunoreactivity: limitations of antibody-based approaches for verification of peptide expression. Peptides. 1996; 17(5):881-3. PMID: 8844781.
      Citations:    
    133. Zia F, Jacobs S, Kull F, Cuttitta F, Mulshine JL, Moody TW. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem Suppl. 1996; 24:269-75. PMID: 8806109.
      Citations:    
    134. Dearing MP, Englee-Miller MJ, Kratzke RA, Kramer BS, Chu E, Weinstein J, Anderson M, Venzon D, Mulshine JL, Gazdar AF. Dipyridamole mediated enhanced antiproliferative activity of 10-ethyl-10-deazaaminopterin (10-EDAM) against human lung cancer cell lines. J Cell Biochem Suppl. 1996; 24:165-72. PMID: 8806099.
      Citations:    
    135. Mulshine JL, Scott F. Molecular markers in early cancer detection. New screening tools. Chest. 1995 Jun; 107(6 Suppl):280S-286S. PMID: 7781406.
      Citations:    
    136. Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst. 1995 May 17; 87(10):756-61. PMID: 7563154.
      Citations:    
    137. Avis I, Mathias A, Unsworth EJ, Miller MJ, Cuttitta F, Mulshine JL, Jakowlew SB. Analysis of small cell lung cancer cell growth inhibition by 13-cis-retinoic acid: importance of bioavailability. Cell Growth Differ. 1995 May; 6(5):485-92. PMID: 7647031.
      Citations:    
    138. Battey JF, Brown PH, Gritz ER, Hong WK, Johnson BE, Karp DD, Mulshine JL, Shaw GL, Shopland DR, Sunday ME, et al. Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop. Lung Cancer. 1995 Mar; 12(1-2):91-103. PMID: 7600036.
      Citations:    
    139. Mulshine JL. Fostering chemopreventive agent development: how to proceed? J Cell Biochem Suppl. 1995; 22:254-9. PMID: 8538207.
      Citations:    
    140. Tockman MS, Erozan YS, Gupta P, Piantadosi S, Mulshine JL, Ruckdeschel JC. The early detection of second primary lung cancers by sputum immunostaining. LCEWDG Investigators. Lung Cancer Early Detection Group. Chest. 1994 Dec; 106(6 Suppl):385S-390S. PMID: 7988270.
      Citations:    
    141. Kelley MJ, Mulshine JL. Anticancer antibodies for lung cancer. J Clin Oncol. 1994 Nov; 12(11):2519-20. PMID: 7818695.
      Citations:    
    142. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct; 12(10):2022-34. PMID: 7931470.
      Citations:    
    143. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 1994 Sep; 9(9):2441-8. PMID: 8058306.
      Citations:    
    144. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994 May 01; 54(9):2496-503. PMID: 7909277.
      Citations:    
    145. Green M, Brodin O, Choi N, Drings P, Ginsberg R, Gralla R, Johnson D, Mulshine J, Payne D, Ruffi? P. Pre-operative and post-operative treatments in stage III NSCLC. Lung Cancer. 1994 Mar; 10 Suppl 1:S15-7. PMID: 8087504.
      Citations:    
    146. Souhami RL, Brodin O, Duchesne G, Goldie J, Green M, Kies M, Mattson K, Mulshine J, Saijo N, Saunders M, et al. Second IASLC Workshop on Combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Biological basis of combined therapy. Lung Cancer. 1994 Mar; 10 Suppl 1:S3-5. PMID: 8087524.
      Citations:    
    147. Mulshine JL, Johnson BE, Gazdar AF, Shaw GL, Kramer BS, Mitsudomi T, Minna JD, Pass H, Phelps R, Ghosh B, et al. Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer. 1994 Mar; 10 Suppl 1:S73-81. PMID: 8087530.
      Citations:    
    148. Tockman MS, Gupta PK, Pressman NJ, Mulshine JL. Cytometric validation of immunocytochemical observations in developing lung cancer. Diagn Cytopathol. 1993 Dec; 9(6):615-22. PMID: 8143533.
      Citations:    
    149. Treston AM, Scott FM, Vos M, Iwai N, Mains RE, Eipper BA, Cuttitta F, Mulshine JL. Biochemical characterization of peptide alpha-amidation enzyme activities of human neuroendocrine lung cancer cell lines. Cell Growth Differ. 1993 Nov; 4(11):911-20. PMID: 8297797.
      Citations:    
    150. Szabo E, Birrer MJ, Mulshine JL. Early detection of lung cancer. Semin Oncol. 1993 Aug; 20(4):374-82. PMID: 8342067.
      Citations:    
    151. Mulshine JL, Jett M, Cuttitta F, Treston AM, Quinn K, Scott F, Iwai N, Avis I, Linnoila RI, Shaw GL. Scientific basis for cancer prevention. Intermediate cancer markers. Cancer. 1993 Aug 01; 72(3 Suppl):978-83. PMID: 8334673.
      Citations:    
    152. Shaw GL, Mulshine JL. Monoclonal antibodies for early cytologic detection of lung cancer. Semin Thorac Cardiovasc Surg. 1993 Jul; 5(3):201-9. PMID: 8353148.
      Citations:    
    153. Szabo E, Mulshine J. Epidemiology, prognostic factors, and prevention of lung cancer. Curr Opin Oncol. 1993 Mar; 5(2):302-9. PMID: 8457617.
      Citations:    
    154. Avis I, Jett M, Kasprzyk PG, Cuttitta F, Treston AM, Maneckjee R, Mulshine JL. Effect of gastrin-releasing peptide on the pancreatic tumor cell line (Capan). Mol Carcinog. 1993; 8(4):214-20. PMID: 8280369.
      Citations:    
    155. Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GL. Initiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S. PMID: 8380133.
      Citations:    
    156. Scott F, Cuttitta F, Treston AM, Avis I, Gupta P, Ruckdeschel J, Kelly K, Piantadosi S, Tockman M, Mulshine J. Prospective trial evaluating immunocytochemical-based sputum techniques for early lung cancer detection: assays for promotion factors in the bronchial lavage. J Cell Biochem Suppl. 1993; 17F:175-83. PMID: 8412189.
      Citations:    
    157. Gross AJ, Steinberg SM, Reilly JG, Bliss DP, Brennan J, Le PT, Simmons A, Phelps R, Mulshine JL, Ihde DC, et al. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res. 1993 Jan 01; 53(1):67-74. PMID: 8380126.
      Citations:    
    158. Kim J, Kaye FJ, Henslee JG, Shively JE, Park JG, Lai SL, Linnoila RI, Mulshine JL, Gazdar AF. Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer. 1992 Nov 11; 52(5):718-25. PMID: 1330929.
      Citations:    
    159. Siegfried JM, Kasprzyk PG, Treston AM, Mulshine JL, Quinn KA, Cuttitta F. A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone. Proc Natl Acad Sci U S A. 1992 Sep 01; 89(17):8107-11. PMID: 1325646.
      Citations:    
    160. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992 Jun; 53(6):992-8. PMID: 1317697.
      Citations:    
    161. Mulshine JL. Overview: NCI Workshop on Investigational Strategies for Detection and Intervention in Early Lung Cancer. Cancer Res. 1992 May 01; 52(9 Suppl):2639s-2640s. PMID: 1348661.
      Citations:    
    162. Tockman MS, Gupta PK, Pressman NJ, Mulshine JL. Considerations in bringing a cancer biomarker to clinical application. Cancer Res. 1992 May 01; 52(9 Suppl):2711s-2718s. PMID: 1563002.
      Citations:    
    163. Mulshine JL, Tockman MS. Diagnostic research: breakout group report. Cancer Res. 1992 May 01; 52(9 Suppl):2766s. PMID: 1563010.
      Citations:    
    164. Mulshine JL, Shuke N, Daghighian F, Carrasquillo J, Ghosh B, Walsh T, Avis I, Reynolds JC, Cuttitta F, Larson SM. The correct dose: pharmacologically guided end point for anti-growth factor therapy. Cancer Res. 1992 May 01; 52(9 Suppl):2743s-2746s. PMID: 1314137.
      Citations:    
    165. Linnoila RI, Jensen SM, Steinberg SM, Mulshine JL, Eggleston JC, Gazdar AF. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol. 1992 Feb; 97(2):233-43. PMID: 1372146.
      Citations:    
    166. Mulshine JL, Linnoila RI, Jensen SM, Magnani JL, Tockman MS, Gupta PK, Scott FS, Avis I, Quinn K, Birrer MJ, et al. Rational targets for the early detection of lung cancer. J Natl Cancer Inst Monogr. 1992; (13):183-90. PMID: 1389692.
      Citations:    
    167. Linnoila RI, Mulshine JL, Steinberg SM, Gazdar AF. Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. J Natl Cancer Inst Monogr. 1992; (13):61-6. PMID: 1327036.
      Citations:    
    168. Treston AM, Mulshine JL, Cuttitta F. Control of tumor cell biology through regulation of peptide hormone processing. J Natl Cancer Inst Monogr. 1992; (13):169-75. PMID: 1389690.
      Citations:    
    169. Mulshine JL, Birrer M, Treston AM, Scott F, Quinn K, Avis I, Cuttitta F. Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8. PMID: 1442286.
      Citations:    
    170. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992 Jan; 7(1):171-80. PMID: 1311061.
      Citations:    
    171. Gazdar AF, Kadoyama C, Venzon D, Park JG, Tsai CM, Linnoila RI, Mulshine JL, Ihde DC, Giaccone G. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr. 1992; (13):191-6. PMID: 1327032.
      Citations:    
    172. Mulshine JL, Linnoila RI, Treston AM, Scott FM, Quinn K, Avis I, Shaw GL, Jensen SM, Brown P, Birrer MJ, et al. Candidate biomarkers for application as intermediate end points of lung carcinogenesis. J Cell Biochem Suppl. 1992; 16G:183-6. PMID: 1469899.
      Citations:    
    173. Quinn KA, Treston AM, Scott FM, Kasprzyk PG, Avis I, Siegfried JM, Mulshine JL, Cuttitta F. Alpha-amidation of peptide hormones in lung cancer. Cancer Cells. 1991 Dec; 3(12):504-10. PMID: 1668141.
      Citations:    
    174. Avis IL, Kovacs TO, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine JL. Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer. J Natl Cancer Inst. 1991 Oct 16; 83(20):1470-6. PMID: 1656058.
      Citations:    
    175. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, Pass H, Minna JD, Gazdar AF. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991 Sep 15; 51(18):4999-5002. PMID: 1654209.
      Citations:    
    176. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991 Aug; 6(8):1353-62. PMID: 1679529.
      Citations:    
    177. Manderino GL, Leicht JC, Mulshine JL, Gooch GT. Cross validation of cluster analysis using immunostained multi-tissue tumour block slides. Br J Cancer Suppl. 1991 Jun; 14:60-3. PMID: 1645574.
      Citations:    
    178. Mulshine JL, Treston AM, Scott FM, Avis I, Boland C, Phelps R, Kasprzyk PG, Nakanishi Y, Cuttitta F. Lung cancer: rational strategies for early detection and intervention. Oncology (Williston Park). 1991 May; 5(5):25-32; discussion 32-3, 37. PMID: 1832003.
      Citations:    
    179. Whang-Peng J, Knutsen T, Gazdar A, Steinberg SM, Oie H, Linnoila I, Mulshine J, Nau M, Minna JD. Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes Cancer. 1991 May; 3(3):168-88. PMID: 1651103.
      Citations:    
    180. Mahmoud S, Staley J, Taylor J, Bogden A, Moreau JP, Coy D, Avis I, Cuttitta F, Mulshine JL, Moody TW. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo. Cancer Res. 1991 Apr 01; 51(7):1798-802. PMID: 1848479.
      Citations:    
    181. Mulshine JL, Carrasquillo JA, Weinstein JN, Keenan AM, Reynolds JC, Herdt J, Bunn PA, Sausville E, Eddy J, Cotelingam JD, et al. Direct intralymphatic injection of radiolabeled 111In-T101 in patients with cutaneous T-cell lymphoma. Cancer Res. 1991 Jan 15; 51(2):688-95. PMID: 1985786.
      Citations:    
    182. Phelps RM, Dearing MP, Mulshine JL. Need for uniformity in collection and reporting of data in cancer clinical trials. J Natl Cancer Inst. 1990 Sep 05; 82(17):1377-8. PMID: 2201780.
      Citations:    
    183. Gazdar AF, Linnoila RI, Kurita Y, Oie HK, Mulshine JL, Clark JC, Whitsett JA. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 1990 Sep 01; 50(17):5481-7. PMID: 2386953.
      Citations:    
    184. Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 1990 Sep; 87(17):6698-702. PMID: 2168554.
      Citations:    
    185. Dmitrovsky E, Seifter EJ, Gazdar AF, Tsai CM, Edison M, Brantley P, Veach SR, Batist G, Ihde DC, Mulshine JL. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity. Am J Clin Oncol. 1990 Aug; 13(4):285-9. PMID: 2165737.
      Citations:    
    186. Dearing MP, Steinberg SM, Phelps R, Anderson MJ, Mulshine JL, Ihde DC, Johnson BE. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol. 1990 Jun; 8(6):1042-9. PMID: 2161447.
      Citations:    
    187. Gazdar AF, Mulshine JL, Kramer BS. Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. Immunol Ser. 1990; 53:453-68. PMID: 1966068.
      Citations:    
    188. Kyogashima M, Mulshine J, Linnoila RI, Jensen S, Magnani JL, Nudelman E, Hakomori S, Ginsburg V. Antibody 624H12, which detects lung cancer at early stages, recognizes a sugar sequence in the glycosphingolipid difucosylneolactonorhexaosylceramide (V3FucIII3FunLc6Cer). Arch Biochem Biophys. 1989 Nov 15; 275(1):309-14. PMID: 2554809.
      Citations:    
    189. Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson BE, Mulshine JL, Ihde DC, Kayser K, Gazdar AF. MDR1 gene expression in lung cancer. J Natl Cancer Inst. 1989 Aug 02; 81(15):1144-50. PMID: 2746668.
      Citations:    
    190. Mulshine JL, Treston AM, Natale RB, Kasprzyk PG, Avis I, Nakanishi Y, Cuttitta F. Autocrine growth factors as therapeutic targets in lung cancer. Chest. 1989 Jul; 96(1 Suppl):31S-34S. PMID: 2661168.
      Citations:    
    191. Mulshine JL, Tockman MS, Smart CR. Considerations in the development of lung cancer screening tools. J Natl Cancer Inst. 1989 Jun 21; 81(12):900-6. PMID: 2659802.
      Citations:    
    192. Tsai CM, Gazdar AF, Venzon DJ, Steinberg SM, Dedrick RL, Mulshine JL, Kramer BS. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Cancer Res. 1989 May 01; 49(9):2390-7. PMID: 2706626.
      Citations:    
    193. Treston AM, Mulshine JL. Peptide structure. Beyond transcriptional events. Nature. 1989 Feb 02; 337(6206):406. PMID: 2644539.
      Citations:    
    194. Mulshine JL, Natale RB, Avis I, Treston AM, Kasprzyk PG, Nakanishi Y, Sausville EA, Trepel JB, Cuttitta F. Autocrine growth factors and lung cancer. Cancer Treat Res. 1989; 45:107-22. PMID: 2577167.
      Citations:    
    195. Mulshine JL, Avis I, Treston AM, Kaspryzyk PG, Nakanishi Y, Mobley C, Carrasquillo JA, Larson SM, Merchant B, Cuttitta F. In vivo diagnosis and therapy of human tumors with monoclonal antibodies: selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung. Int J Rad Appl Instrum B. 1989; 16(2):159-62. PMID: 2541112.
      Citations:    
    196. Linnoila RI, Mulshine JL, Steinberg SM, Funa K, Matthews MJ, Cotelingam JD, Gazdar AF. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol. 1988 Dec; 90(6):641-52. PMID: 2848408.
      Citations:    
    197. Trepel JB, Moyer JD, Cuttitta F, Frucht H, Coy DH, Natale RB, Mulshine JL, Jensen RT, Sausville EA. A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. Biochem Biophys Res Commun. 1988 Nov 15; 156(3):1383-9. PMID: 2847733.
      Citations:    
    198. Tockman MS, Gupta PK, Myers JD, Frost JK, Baylin SB, Gold EB, Chase AM, Wilkinson PH, Mulshine JL. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol. 1988 Nov; 6(11):1685-93. PMID: 2846790.
      Citations:    
    199. Kasprzyk PG, Cuttitta F, Avis I, Nakanishi Y, Treston A, Wong H, Walsh JH, Mulshine JL. Solid-phase peptide quantitation assay using labeled monoclonal antibody and glutaraldehyde fixation. Anal Biochem. 1988 Oct; 174(1):224-34. PMID: 3146232.
      Citations:    
    200. Makuch RW, Rosenberg PS, Mulshine J. Identifying prognostic factors in binary outcome data: an application using liver function tests and age to predict liver metastases. Stat Med. 1988 Aug; 7(8):843-56. PMID: 2842852.
      Citations:    
    201. Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988 Jul 15; 48(14):4078-82. PMID: 3383200.
      Citations:    
    202. Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest. 1988 Jul; 82(1):354-9. PMID: 2839551.
      Citations:    
    203. Kasprzyk PG, Cuttitta F, Treston AM, Avis I, Nakanishi Y, Wong H, Walsh JH, Mulshine JL. Consideration of the chemistry of solid-phase matrix interaction leads to improved quantitation of neuropeptides. Ann N Y Acad Sci. 1988; 547:41-53. PMID: 3239893.
      Citations:    
    204. Nakanishi Y, Cuttitta F, Kasprzyk PG, Avis I, Steinberg SM, Gazdar AF, Mulshine JL. Growth factor effects on small cell lung cancer cells using a colorimetric assay: can a transferrin-like factor mediate autocrine growth? Exp Cell Biol. 1988; 56(1-2):74-85. PMID: 2846378.
      Citations:    
    205. Minna JD, Cuttitta F, Battey JF, Mulshine JL, Linnoila I, Gazdar AF, Trepel J, Sausville EA. Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications. Important Adv Oncol. 1988; 55-64. PMID: 3042610.
      Citations:    
    206. Mulshine JL, Avis I, Treston AM, Mobley C, Kaspryzyk P, Carrasquillo JA, Larson SM, Nakanishi Y, Merchant B, Minna JD, et al. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann N Y Acad Sci. 1988; 547:360-72. PMID: 2853598.
      Citations:    
    207. Doyle LA, Cuttitta F, Mulshine JL, Bunn PA, Minna JD. Markedly different antibody responses to immunized small cell and non-small cell lung cancer cells. Cancer Res. 1987 Oct 01; 47(19):5009-13. PMID: 3040237.
      Citations:    
    208. Mulshine JL, Keenan AM, Carrasquillo JA, Walsh T, Linnoila RI, Holton OD, Harwell J, Larson SM, Bunn PA, Weinstein JN. Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging. Cancer Res. 1987 Jul 01; 47(13):3572-6. PMID: 3472655.
      Citations:    
    209. Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M, et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med. 1987 Mar; 28(3):281-7. PMID: 3102699.
      Citations:    
    210. Keenan AM, Weinstein JN, Mulshine JL, Carrasquillo JA, Bunn PA, Reynolds JC, Larson SM. Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody. J Nucl Med. 1987 Jan; 28(1):42-6. PMID: 3794811.
      Citations:    
    211. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, Larson SM, Keenan AM. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci. 1987; 507:199-210. PMID: 3327413.
      Citations:    
    212. Mulshine JL, Glatstein E, Ruckdeschel JC. Treatment of non-small-cell lung cancer. J Clin Oncol. 1986 Nov; 4(11):1704-15. PMID: 2430072.
      Citations:    
    213. Carrasquillo JA, Bunn PA, Keenan AM, Reynolds JC, Schroff RW, Foon KA, Su MH, Gazdar AF, Mulshine JL, Oldham RK, et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med. 1986 Sep 11; 315(11):673-80. PMID: 3489185.
      Citations:    
    214. Spitalnik SL, Spitalnik PF, Dubois C, Mulshine J, Magnani JL, Cuttitta F, Civin CI, Minna JD, Ginsburg V. Glycolipid antigen expression in human lung cancer. Cancer Res. 1986 Sep; 46(9):4751-5. PMID: 2425958.
      Citations:    
    215. Hsu SM, Huang LC, Hsu PL, Ge ZH, Ho YS, Cuttita F, Mulshine J. Biochemical and ultrastructural study of Leu M1 antigen in Reed-Sternberg cells: comparison with granulocytes and interdigitating reticulum cells. J Natl Cancer Inst. 1986 Aug; 77(2):363-70. PMID: 3090338.
      Citations:    
    216. Fargion S, Carney D, Mulshine J, Rosen S, Bunn P, Jewett P, Cuttitta F, Gazdar A, Minna J. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res. 1986 May; 46(5):2633-8. PMID: 3008997.
      Citations:    
    217. Minna JD, Battey JF, Brooks BJ, Cuttitta F, Gazdar AF, Johnson BE, Ihde DC, Lebacq-Verheyden AM, Mulshine J, Nau MM, et al. Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:843-53. PMID: 3472765.
      Citations:    
    218. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985 Aug 29-Sep 4; 316(6031):823-6. PMID: 2993906.
      Citations:    
    219. Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, Martin SE, Linnoila I, Cuttitta F, Mulshine J, Bunn P, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985 May 01; 161(5):1135-51. PMID: 2580935.
      Citations:    
    220. Gupta PK, Myers JD, Baylin SB, Mulshine JL, Cuttitta F, Gazdar AF. Improved antigen detection in ethanol-fixed cytologic specimens. A modified avidin-biotin-peroxidase complex (ABC) method. Diagn Cytopathol. 1985 Apr-Jun; 1(2):133-6. PMID: 3013531.
      Citations:    
    221. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Autocrine growth factors in human small cell lung cancer. Cancer Surv. 1985; 4(4):707-27. PMID: 2445479.
      Citations:    
    222. Mulshine JL, Tubbs R, Sheeler LR, Gifford RW. Clinical significance of the association of the Von Hippel-Lindau disease with pheochromocytoma and pancreatic apudoma. Am J Med Sci. 1984 Dec; 288(5):212-6. PMID: 6517090.
      Citations:    
    223. Combs SG, Marder RJ, Minna JD, Mulshine JL, Polovina MR, Rosen ST. Immunohistochemical localization of the immunodominant differentiation antigen lacto-N-fucopentaose III in normal adult and fetal tissues. J Histochem Cytochem. 1984 Sep; 32(9):982-8. PMID: 6379043.
      Citations:    
    224. Mulshine JL, Makuch RW, Johnston-Early A, Matthews MJ, Carney DN, Ihde DC, Cohen MH, Bates HR, Dunnick NR, Minna JD, et al. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol. 1984 Jul; 2(7):733-41. PMID: 6330314.
      Citations:    
    225. Rosen ST, Mulshine JL, Cuttitta F, Fedorko J, Carney DN, Gazdar AF, Minna JD. Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies. Cancer Res. 1984 May; 44(5):2052-61. PMID: 6713399.
      Citations:    
    226. Mulshine JL, Cuttitta F, Bibro M, Fedorko J, Fargion S, Little C, Carney DN, Gazdar AF, Minna JD. Monoclonal antibodies that distinguish non-small cell from small cell lung cancer. J Immunol. 1983 Jul; 131(1):497-502. PMID: 6306102.
      Citations:    
    227. Mulshine J, Lucas FV, Clough JD. Platelet-bound IgG in systemic lupus erythematosus with and without thrombocytopenia. J Immunol Methods. 1981; 45(3):275-81. PMID: 7288196.
      Citations:    
    Mulshine's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (708)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _